An Expanded Access Program for AM0010 (Pegilodecakin)
- Conditions
- Ovarian CancerPancreatic CarcinomaBreast CancerNon-small Cell Lung CarcinomaSolid TumorsMelanomaProstate CancerColorectal CarcinomaRenal Cell Carcinoma
- Registration Number
- NCT03554434
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of Pegilodecakin demonstrate anti-tumor activity in advanced ovarian cancer?
How does Pegilodecakin compare to standard-of-care therapies in metastatic pancreatic carcinoma progression?
Which biomarkers correlate with response to Pegilodecakin in patients with refractory non-small cell lung cancer?
What adverse events are associated with Pegilodecakin subcutaneous administration in solid tumor patients?
Are there combination therapies involving Pegilodecakin and immune checkpoint inhibitors for advanced melanoma?